Mice with Inactivation of Aryl Hydrocarbon Receptor-Interacting Protein ( Aip ) Display Complete Penetrance of Pituitary Adenomas with Aberrant ARNT Expression
Mutations in the aryl hydrocarbon receptor-interacting protein ( AIP ) gene have been shown to predispose to pituitary adenoma predisposition, a condition characterized by growth hormone (GH)-secreting pituitary tumors. To study AIP -mediated tumorigenesis, we generated an Aip mouse model. Heterozyg...
Gespeichert in:
Veröffentlicht in: | The American journal of pathology 2010-10, Vol.177 (4), p.1969-1976 |
---|---|
Hauptverfasser: | , , , , , , , , , |
Format: | Artikel |
Sprache: | eng |
Schlagworte: | |
Online-Zugang: | Volltext |
Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
Zusammenfassung: | Mutations in the aryl hydrocarbon receptor-interacting protein ( AIP ) gene have been shown to predispose to pituitary adenoma predisposition, a condition characterized by growth hormone (GH)-secreting pituitary tumors. To study AIP -mediated tumorigenesis, we generated an Aip mouse model. Heterozygous mice developed normally but were prone to pituitary adenomas, in particular to those secreting GH. A complete loss of AIP was detected in these lesions, and full penetrance was reached at the age of 15 months. No excess of any other tumor type was found. Ki-67 analysis indicated that Aip -deficient tumors have higher proliferation rates compared with Aip -proficient tumors, suggesting a more aggressive disease. Similar to human AIP -deficient pituitary adenomas, immunohistochemical studies showed that expression of aryl hydrocarbon receptor nuclear translocator 1 or 2 (ARNT or ARNT2) protein was lost in the mouse tumors, suggesting that mechanisms of AIP -related tumorigenesis involve aberrant ARNT function. The Aip+/− mouse appears to be an excellent model for the respective human disease phenotype. This model constitutes a tool to further study AIP -associated pituitary tumorigenesis and may be potentially valuable in efforts to develop therapeutic strategies to treat pituitary adenomas. |
---|---|
ISSN: | 0002-9440 1525-2191 |
DOI: | 10.2353/ajpath.2010.100138 |